

105 Rec'd PCT/PTO 23 JUN 1997

(1390 REV. 5-83) US DEPT. OF COMMERCE PATENT & TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER
WPB 39818

**TRANSMITTAL LETTER TO THE
UNITED STATES
DESIGNATED/ELECTED OFFICE
(DO/EO/US) CONCERNING A FILING
UNDER 35 U.S.C. 371**

U.S. APPLICATION NO.
(if known, sec 37 C.F.R.1.5)**08/860231**INTERNATIONAL APPLICATION NO.
PCT/FR96/00037INTERNATIONAL FILING DATE
January 9, 1996PRIORITY DATE CLAIMED
January 9, 1995TITLE OF INVENTION
NUTRIENT MEDIUM WHICH CAN BE USED AS A CULTURE MEDIUM FOR EPIDERMAL CELLS AND APPLICATIONSAPPLICANT(S) FOR DO/EO/US
Jean-Noel THOREL and Hugues GATTO

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☒ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A small entity statement.
16. ☐ Other items or information:

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5)

INTERNATIONAL APPLICATION NO.
PCT/FR96/00037

ATTORNEY'S DOCKET NUMBER
WPB 39818

17. ☒ The following fees are submitted:

Basic National fee (37 CFR 1.492(a)(1)-(5)):

Search Report has been prepared by the EPO or JPO.....\$910.00

International preliminary examination fee paid to USPTO (37 CFR 1.482).....\$700.00

No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)).....\$770.00

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$1,040.00

International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4).....\$ 96.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

Claims	Number Filed	Number Extra	Rate
Total Claims	20- 20 =	---	X \$ 22.00
Independent Claims	2- 3 =	---	X \$ 80.00
Multiple dependent claim(s)(if applicable)			+ \$260.00

TOTAL OF ABOVE CALCULATIONS =

Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).

SUBTOTAL =

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 month from the earliest claimed priority date (37 CFR 1.492(f)).

TOTAL NATIONAL FEE =

Amount to be
refunded \$

Charged \$

- a. ☒ Check No. 53970 in the amount of \$455.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. _____ in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 15-0461. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

OLIFF & BERRIDGE
P.O. Box 19928
Alexandria, Virginia 22320

NAME: William P. Berridge
REGISTRATION NUMBER: 30,024

NAME: Joel S. Armstrong
REGISTRATION NUMBER: 36,430

08/860231

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Jean-Noel THOREL and Hugues GATTO

Application No.: NEW U.S. NATIONAL APPLICATION
OF PCT/FR96/00037

Filed: June 23, 1997

Docket No.: WPB 39818

For: NUTRIENT MEDIUM WHICH CAN BE USED AS A CULTURE MEDIUM
FOR EPIDERMAL CELLS AND APPLICATIONS

pre 1/2 AA

PRELIMINARY AMENDMENTAssistant Commissioner of Patents
Washington, D. C. 20231

Sir:

Prior to initial examination, please amend the above-identified application as follows:

IN THE CLAIMS:

Please amend claims 4, 7, 12-15 and 18 as follows.

Claim 4, line 4, change "any one of Claims 1 to 3"
to --Claim 1--.

Claim 7, line 2, change "any one of Claims 4 to 6"
to --Claim 4--.

Claim 12, line 1, change "any one of Claims 9 to
11," to --Claim 9,--.

Claim 13, line 1, change "any one of Claims 9 to
12," to --Claim 9,--.

Claim 14, line 1, change "any one of Claims 9 to
13," to --Claim 9,--.


Claim 15, line 4, change "any one of Claims 9 to 11"
to --Claim 9--.

Claim 18, line 2, change "any one of Claims 15 to 17" to --Claim 15--.

REMARKS

Claims 1-18 and 20-21 are pending. This Preliminary Amendment eliminates multiple dependent claims. Prompt and favorable examination on the merits is respectfully requested.

Respectfully submitted,


William P. Berridge
Registration No. 30,024

Joel S. Armstrong
Registration No. 36,430

OLIFF & BERRIDGE
P.O. Box 19928
Alexandria, Virginia 22320
Telephone: (703) 836-6400

WO 96/21421

- 1 -

PCT/FR96/00037

Complete Medium For Use As A Cosmetic And Cosmetic Use Thereof
~~Nutrient medium which can be used as a culture medium~~
~~for epidermal cells and applications~~

The present invention relates to a complex nutrient medium, to its applications and more especially to its use for manufacturing a composition for topical use, and in particular for topical cosmetic or medicinal use.

The composition obtained according to the invention enables an extracellular environment which is entirely suited to the epidermis to be obtained, by supplying in particular:

- an optimized nutritional provision, both in respect of vitamins, ~~and~~ trace elements and ~~in respect of essential amino acids~~ *other components*
- ~~cell growth factors directed towards replacing the morphogenic cellular interactions,~~
- and pH and osmolarity characteristics close to physiological conditions.

Generally speaking, according to the invention, the nutritional agent consists of a complex nutrient medium comprising compounds which are both biocompatible, biomimetic and bioavailable in respect of the skin, excluding any biological extract of animal origin, such as foetal calf serum, or of cellular origin.

The complex nutrient medium adopted according to the invention has a composition suitable for permitting, on its own and in an aqueous medium, viable in vitro culture of an inoculum of human epidermal keratinocytes, with at least one clonal proliferation of the latter at the first passage, without a living nourishing substrate such as fibroblasts.

"Biocompatible" is understood to mean the property according to which the compound is harmless to the skin.

"Biomimetic" is understood to mean the fact that the compound is present in the natural state in the skin.

"Bioavailable" is understood to mean the property according to which the compound is assimilable by human epidermal keratinocytes, both in vitro and in vivo.

SECRET - 07597

B
B

By routine tests, a person skilled in the art is in a position to formulate a complex nutrient medium according to the invention, in particular by carrying out with the said medium in vitro culturing of keratinocytes, the growth of which can be observed, for example under a microscope.

In this connection, the following documents have already described media suited to in vitro culturing of keratinocytes, the viability and growth of which can be determined by the tests currently in use, and be directly assessed by observation under a microscope:

- Boyce ST, Ham RG, Calcium-regulated differentiation of normal human epidermal keratinocytes in defined clonal culture and serum-free serial culture, J. Invest. Dermatol. 1983; 81: 33S-40S

- Boyce ST, Ham RG, Cultivation, frozen storage, and clonal growth of normal human epidermal keratinocytes ⁱⁿ ~~in~~ serum-free media, J. Tissue Culture Methods. 1985; 9: 83-93.

Where necessary, the content of these publications is incorporated in the present description.

The complex nutrient medium according to the invention comprises amino acids, one or more vitamins, one or more ~~cell growth factors~~ ^{organic components} and one or more inorganic salts.

A composition of the invention for topical use comprises a phase which is biocompatible with the superficial parts of the human body, in which phase at least the said nutrient medium as defined above is distributed homogeneously.

In a composition according to the present invention, the biocompatible phase in which the nutritional agent is distributed can constitute the excipient, or one of the components of the excipient, of the said composition.

Since all of the compounds present in the nutrient medium according to the invention are water-soluble, two methods of formulation may be employed in order to obtain a composition for topical use:

1) Aqueous continuous phase, containing the nutrient medium according to the invention:

- in the form of an aqueous gel, with the aid of a nonionic water-soluble polymer of the polysaccharide or cellulose ether type (polymers compatible with the high ionic strength of the medium);

- in the form of an emulsified system (oil-in-water emulsion employing surfactants that withstand high ionic strengths);

- in the form of a cosmetic serum.

2) Oily continuous phase, the discontinuous phase containing the nutrient medium according to the invention:

- in emulsified form, on the understanding that the ionic strength of the discontinuous phase entails instability of the emulsion; it is, however, possible to formulate lamellar or cylindrical phases having better stability, or alternatively a two-phase system re-emulsified immediately before use by simple shaking;

- by encapsulation:

* in a rigid capsule of the polysaccharide type, dispersed in the lipid phase,

* in a soft capsule of the gelatin type, dispersed in the discontinuous phase.

The use of liposomes as an encapsulation delivery agent can be envisaged in the form of a liposomal gel in an aqueous continuous phase.

A composition according to the invention can serve as a cosmetic base. Its nutritional provision is considerably advantageous for improvement of the viability, maintenance of the integrity and the balance of the superficial cells of the skin. In particular, it enables the primary intrinsic qualities of the skin to be preserved on a long-lasting basis, its resistance to damage to be increased and, where appropriate, its return to a state of balance to be promoted.

Another subject of the invention is a cosmetic preparation comprising a base defined above, in which the complex nutrient medium constitutes either an active

principle, or an excipient in the presence of other active principles which it is capable of potentiating.

The complex nutrient medium of the invention can also be used for the preparation or production of a medicament.

The use of such a medium on a weakened skin (irritated or dehydrated skins, older skins, etc) enables the skin to return to a satisfactory state, in terms both of trophicity and of hydration of the superficial layers of the epidermis.

A medicinal composition comprising a complex nutrient medium according to the invention can serve as a pharmaceutical formulation base, in particular a nutrient pharmaceutical formulation base.

It possesses, in addition, pharmacological properties which will be demonstrated in the examples. According to an advantageous application of a medicinal composition of the invention, it is intended for the preservative treatment of grafts after they are removed. It will preferably take the form of a sterile solution which is especially suitable for the cleaning and maintenance of grafts in third-degree burns victims.

In addition, a composition as defined above has efficacious properties for preventing or treating disorders of cicatrization such as bedsores, varicose ulcers, stretch marks and keloids, and/or a delay of cicatrization.

More generally speaking, a composition according to the invention can be incorporated in any preparation for use in a pharmaceutical formulation, as an active principle optionally with other active principles, but also as an excipient as a result of its capacity to potentiate the action of specific active principles.

The characteristics, applications and advantages of the present invention are described in greater detail in Examples 1 to 4 and Figures 1 to 4 below.

Example 1 gives an example of a formulation of a composition of the invention.

Example 2 demonstrates the properties of a com-

265260-1-1000000000

? NO showing
What's
active
principle?

position of the invention compared to known media, in support of the attached drawing in which:

Fig. 1 is a sectional view of human epidermis after 36 hours of culture in a standard commercial medium designated MCDB 153, marketed, in particular, by IRVINE SCIENTIFIC and GIBCO-BRL,

Fig. 2 is a sectional view of human epidermis after 36 hours of culture in a buffered saline solution (PBS), a balanced saline solution commonly used in cell culture, and

Fig. 3 is a sectional view of human epidermis cultured in the nutrient medium of the invention, described in Example 1, at different culture times:

A : after 12 hours
B : after 24 hours
C : after 36 hours

Example 3 demonstrates the absence of stimulation of the proliferation of transformed cells by a composition of the invention compared to a standard composition, in support of Fig. 4 which depicts a diagram showing the multiplication of transformed cells cultured on a medium of the invention and a standard medium.

Example 4 illustrates the pharmacological properties of a composition of the invention: a) on the treatment of grafts; b) on cicatrization.

Example 1:

Formulation of a composition of the invention

TABLE 1

COMPONENTS		Concentration in mg/l.	
30	Amino acids		
	L-Alanine	9.2	8.91
	L-Arginine HCl ^{HCl} (sic)	421.4	✓
	L-Asparagine (anhydrous)	14.2	13.2
	L-Aspartic acid	4.0	3.99
35	L-Cysteine HCl.H ₂ O	42.0	31.6

	L-Glutamic acid	14.8	14.71
	L-Glutamine	1754.4	877.2
	Glycine	7.6	3.51
	L-Histidine HCl.H ₂ O	50.0	36.1
5	L-Isoleucine	6.0	33.0
	L-Leucine	131.2	132
	L-Lysine HCl	54.0	36.6
	L-Methionine	13.5	25.0
	L-Phenylalanine	10.0	20.0
10	L-Proline	34.6	34.53
	L-Serine	126.1	✓
	L-Threonine	24.0	23.8
	L-Tryptophan	9.3	40.8
	L-Tyrosine 2 Na 2H ₂ O	11.7	54.0
15	L-Valine	70.3	70.2
	<i>Organic Components</i>		
	Vitamins and cell growth factors		
	d-Biotin	0.02	0.0146
	Folic acid	0.80	0.79
	✓ Nicotinamide	0.04	
20	Ca D-Pantothenate	0.30	.285
	Pyridoxine HCl	0.06	2.0373
	Riboflavin	0.04	0.03704
	Thiamine HCl	0.30	0.3373
	Vitamin B ₁₂	0.41	0.407
25	i-Inositol	18.0	18.2
	Putrescine 2 HCl	0.20	0.1...
	Sodium pyruvate	55.0	✓
	Thymidine	0.73	0.7266
	Adenine (HCl)	24.0	12.16
30	DL-Lipoic acid	0.20	0.2063
	Inorganic components		
	Sodium chloride	6800.0	6600.0
	KCl	112.0	111.8?
	Na ₂ HPO ₄	284.0	536.2
35	CuSO ₄ .5H ₂ O	0.003	0.00025
	Sodium acetate	300.0	(anhydrous) 100.0
	D-Glucose	1080.0	1050.0

000000-000000

15 Example 2:

 The cytocompatibility and the performance features of the complex nutrient medium described in Example 1 were tested on cultures of human keratinocytes in a monolayer, and on human epidermis reconstituted in vitro.

20 The nutrient medium according to Example 1 permits the culture of keratinocytes in a monolayer under optimal conditions of viability for at least 36 hours without the slightest cytotoxic effect manifesting

25 itself.

 In contrast, a traditional survival solution such as PBS (phosphate buffered saline, a balanced saline solution commonly used in cell culture) proves cytotoxic from 12 hours of incubation onwards.

30 In agreement with Fig. 3, the nutrient medium according to the example permits culture of normal human epidermis reconstituted under optimal conditions of viability, without cytotoxic manifestations even after 36 hours (Fig. 3C) of contact. The cultures displayed

35 basal, prickle, mast and intact, orthokeratotic cornified cell layers, of regular and normal stratification.

On comparing Fig. 3C with Fig. 1, the latter

5 In contrast, the use of PBS induces, in agreement with Fig. 2, the appearance of keratinocytes in a terminal phase of differentiation at the level of the basal and prickle strata, with more or less pronounced signs of necrosis. A total detachment of the epidermis is also noted, with complete loss of structuring of the
10 different keratinocytic strata.

The composition used for this study is the one described in Example 1, comprising the medium termed medium 1.

The cells are first inoculated into the standard medium and grow until the 2nd day after inoculation into this medium. On the 2nd day, the batch of cells is divided into two, one batch continuing to be cultured in standard medium, the other in medium 1.

The morphology of the cells differs according to the medium employed. That of the cells cultured in medium 1 resembles more closely that obtained using a

semi-defined medium for epithelial cells, of the GIBCO-BRL KSFM type (cells with looser junctions, less pavement appearance, etc).

5 No significant difference is noted in the growth of this line in accordance with the different media, up to confluence (days 6 to 7, not shown here).

It is concluded that the composition 1 has no stimulatory effect on the proliferation of transformed keratinocytes.

10 Example 4: Effects of a composition of the invention on the taking of human skin grafts and the prevention of cicatrization disorders.

The composition tested is the one described in Example 1, comprising the medium termed medium 1.

15 The effects of the composition 1 on the taking of human skin grafts and the prevention of cicatrization disorders were studied on a mouse model (athymic mouse lacking cell-mediated immunity).

20 Two types of grafts were employed: cultured epidermis and human skins originating from plastic surgery. The grafts were irrigated for 30 days with 1 ml of composition 1 (one application daily) for the group A mice and 1 ml of buffered saline solution (PBS) for the group B mice (20 animals per group). Compresses of tulle gras were applied after each irrigation in order to prevent the grafts from drying out.

25 A clinical observation of the grafts was carried out on D-7, D-15 and D-30.

30 Two parameters were evaluated: the necrosis of the cultured epidermis and the cicatrization.

a) the necrosis of the cultured epidermis ("taking of grafts")

35 Scoring is performed from 0 to 3: 0 = no sign of necrosis; 1 = slight inflammation and superficial degradation of the graft; 2 = partial necrosis; 3 = total necrosis.

The results are collated in Table 2.

TABLE 2

GROUP A MICE

(20 grafts in total, treated with the nutrient composition)

5	Score	D-7	D-15	D-30
	0	9/20	12/20	16/20
	1	7/20	4/20	0/20
	2	3/20	2/20	2/20
	3	1/20	2/20	2/20

10 GROUP B MICE

(20 grafts treated with the buffered saline solution)

15	Score	D-7	D-15	D-30
	0	2/20	4/20	7/20
	1	8/20	6/20	3/20
	2	6/20	5/20	5/20
	3	4/20	5/20	5/20

The composition 1 improves the taking of the grafts of cultured human epidermis on athymic mice compared to a traditional survival solution (PBS). Significant differences are noted from 7 days of treatment onwards, for a final improvement of more than 50%.

b) the cicatrization (with the grafted whole skins)

Scoring is performed from 0 to 3: 0 = no cicatrization disorder; 1 = delay of cicatrization; 2 = delay with abnormality of the cicatrization (granulation of the cicatrix); 3 = hypertrophic cicatrix.

The results are collated in Table 3.

TABLE 3

GROUP A MICE

(20 grafted whole skins treated with the nutrient composition)

5

Score	D-7	D-15	D-30
0	20/20	16/20	15/20
1	0/20	3/20	2/20
2	0/20	1/20	2/20
3	0/20	0/20	1/20

10

GROUP B MICE

(20 grafted whole skins treated with the buffered saline solution)

15

Score	D-7	D-15	D-30
0	16/20	10/20	5/20
1	4/20	7/20	8/20
2	0/20	3/20	3/20
3	0/20	0/20	4/20

20

The composition 1 significantly improves the cicatrization processes; this effect is especially marked after 30 days of treatment.

AA34

What is claimed is:
~~CLAIMS~~

a a

~~in response to the second written opinion~~

1. Use of a complex nutrient medium for the manufacture or production of a composition for topical use, the said complex nutrient medium consisting of at least some amino acids, a vitamin, a cell growth factor and an inorganic salt, and excluding any biological extract of animal origin or of cellular origin, the said medium permitting, on its own and in an aqueous medium, viable in vitro culture of an inoculum of human epidermal keratinocytes, with at least one clonal proliferation of the latter at the first passage, without a living nourishing substrate.

2. Use according to Claim 1, characterized in that the components of the nutrient medium are both biocompatible, biomimetic and bioavailable in respect of the skin.

3. Use according to Claim 1, characterized in that the complex nutrient medium has the following composition, the concentration of the components being expressed in mg/l:

Amino acids		
L-Alanine		9.2
L-Arginine HCL [sic]		421.4
L-Asparagine (anhydrous)		14.2
L-Aspartic acid		4.0
L-Cysteine HCL[sic]. H ₂ O		42.0

	L-Glutamic acid	14.8
	L-Glutamine	1754.4
	Glycine	7.6
	L-Histidine HCL[sic]. H ₂ O	50.0
5	L-Isoleucine	6.0
	L-Leucine	131.2
	L-Lysine HCl	54.0
	L-Methionine	13.5
	L-Phenylalanine	10.0
10	L-Proline	34.6
	L-Serine	126.1
	L-Threonine	24.0
	L-Tryptophan	9.3
	L-Tyrosine 2 Na 2H ₂ O	11.7
15	L-Valine	70.3
	Vitamins and cell growth factors	
	d-Biotin	0.02
	Folic acid	0.80
	Nicotinamide	0.04
20	Ca D-Pantothenate	0.30
	Pyridoxine HCl	0.06
	Riboflavin	0.04
	Thiamine HCl	0.30
	Vitamin B ₁₂	0.41
25	i-Inositol	18.0
	Putrescine 2 HCl	0.20
	Sodium pyruvate	55.0
	Thymidine	0.73
	Adenine (HCl)	24.0
30	DL-Lipoic acid	0.20

Inorganic components

	Sodium chloride	6800.0
	KCl	112.0
	Na ₂ HPO ₄	284.0
5	CuSO ₄ .5H ₂ O	0.003
	Sodium acetate	300.0 (anhydrous)
	D-Glucose	1080.0
	HEPES (piperazine)	6600.0
	Phosphorylethanolamine	0.06768
10	Ethanolamine	0.04684
	Sodium sulphate	3.4
	Sodium bicarbonate	1160.0
	FeSO ₄ .7H ₂ O	1.39
	MgCl ₂ .6H ₂ O	120.0
15	CaCl ₂ .2H ₂ O	from 13.0 to 22.05
	ZnSO ₄ .7H ₂ O	0.144
	(NH ₄) ₆ MO ₇ O ₂₄ .4H ₂ O	0.00120
	Na ₂ SiO ₃ .5H ₂ O	0.142
	MnCl ₂ .4H ₂ O	0.00002
20	SnCl ₂ .2H ₂ O	0.00011
	NH ₄ VO ₃	0.00057

aa 25 4. Composition for topical use comprising a phase which is biocompatible with the superficial parts of the human body, in which phase at least one nutrient medium as defined according to ~~any one of Claims 1 to 3~~ ^{claim 1} is distributed homogeneously.

30 5. Composition according to Claim 4, characterized in that it is in two-phase form, with an aqueous continuous phase containing the complex nutrient medium, and in particular in the form of an aqueous gel or an oil-in-water emulsion.

35 6. Composition according to Claim 4, characterized in that it is in two-phase form, with an oily continuous phase, in particular in emulsion form, the discontinuous phase containing the complex nutrient medium.

aa 7. Cosmetic base comprising a composition according to ~~any one of Claims 4 to 6~~.

8. Cosmetic preparation comprising a cosmetic base according to Claim 7, characterized in that the complex nutrient medium constitutes either an active principle, or an excipient, in particular one that potentiates another active principle.

9. Use of a complex nutrient medium having a composition, excluding any biological extract of animal origin or of cellular origin, suitable for permitting, on its own and in an aqueous medium, viable in vitro culture of an inoculum of human epidermal keratinocytes, with at least one clonal proliferation of the latter at the first passage, without a living nourishing substrate, for the manufacture or production of a medicament.

10. Use according to Claim 9, characterized in that the compounds [sic] of the nutrient medium are both biocompatible, biomimetic and bioavailable in respect of the skin.

11. Use according to Claim 9, characterized in that the complex nutrient medium has the following composition, the concentration of the components being expressed in mg/l:

Amino acids		
	L-Alanine	9.2
	L-Arginine HCl	421.4
25	L-Asparagine (anhydrous)	14.2
	L-Aspartic acid	4.0
	L-Cysteine HCl.H ₂ O	42.0

	L-Glutamic acid	14.8
	L-Glutamine	1754.4
	Glycine	7.6
	L-Histidine HCl.H ₂ O	50.0
5	L-Isoleucine	6.0
	L-Leucine	131.2
	L-Lysine HCl	54.0
	L-Methionine	13.5
	L-Phenylalanine	10.0
10	L-Proline	34.6
	L-Serine	126.1
	L-Threonine	24.0
	L-Tryptophan	9.3
	L-Tyrosine 2 Na 2H ₂ O	11.7
15	L-Valine	70.3
	Vitamins and cell growth factors	
	d-Biotin	0.02
	Folic acid	0.80
	Nicotinamide	0.04
20	Ca D-Pantothenate	0.30
	Pyridoxine HCl	0.06
	Riboflavin	0.04
	Thiamine HCl	0.30
	Vitamin B ₁₂	0.41
25	i-Inositol	18.0
	Putrescine 2 HCl	0.20
	Sodium pyruvate	55.0
	Thymidine	0.73
	Adenine (HCl)	24.0
30	DL-Lipoic acid	0.20

Inorganic components

	Sodium chloride	6800.0
	KCl	112.0
	Na ₂ HPO ₄	284.0
5	CuSO ₄ .5H ₂ O	0.003
	Sodium acetate	300.0 (anhydrous)
	D-Glucose	1080.0
	HEPES (piperazine)	6600.0
	Phosphorylethanolamine	0.06768
10	Ethanolamine	0.04684
	Sodium sulphate	3.4
	Sodium bicarbonate	1160.0
	FeSO ₄ .7H ₂ O	1.39
	MgCl ₂ .6H ₂ O	120.0
15	CaCl ₂ .2H ₂ O	from 13.0 to 22.05
	ZnSO ₄ .7H ₂ O	0.144
	(NH ₄) ₆ MO ₇ O ₂₄ .4H ₂ O	0.00120
	Na ₂ SiO ₃ .5H ₂ O	0.142
	MnCl ₂ .4H ₂ O	0.00002
20	SnCl ₂ .2H ₂ O	0.00011
	NH ₄ VO ₃	0.00057

aa 12. Use according to ~~any one of claims 9 to 11~~, characterized in that the nutritional agent constitutes one of the active principles, if not the active principle, of the said medicament.

ac 13. Use according to ~~any one of claims 9 to 12~~, for obtaining a medicament intended for the preservative treatment of grafts.

aa 14. Use according to ~~any one of claims 9 to 13~~, for preventing or treating disorders and/or delay of cicatrization.

35 ac 15. Medicinal composition for topical use, comprising a phase which is biocompatible with the superficial parts of the human body, in which phase at least one nutrient medium as defined according to ~~any one of claims 9 to 11~~ is distributed homogeneously.

16. Composition according to Claim 15, characterized

in that it is in two-phase form, with an aqueous continuous phase containing the complex nutrient medium, and in particular in the form of an aqueous gel or an oil-in-water emulsion.

- 5 17. Composition according to Claim 15, characterized in that it is in two-phase form, with an oily continuous phase, in particular in emulsion form, the discontinuous phase containing the complex nutrient medium.

18. Pharmaceutical formulation base comprising a composition according to ~~any one of claims 15 to 17.~~ *claim 15*

20[sic]. Pharmaceutical formulation base according to Claim 18, characterized in that it is intended for the preservative treatment of grafts.

21[sic]. Pharmaceutical formulation base according to
15 Claim 18, characterized in that it is intended for the prevention or treatment of disorders and/or delay of cicatrization.

*add
a1*

Add B3

Add C2

NUTRIENT MEDIUM FOR USE AS A CULTURE MEDIUM FOR EPIDERMAL CELLS, AND USES THEREOF

Patent Number: WO9621421
Publication date: 1996-07-18
Inventor(s): GATTO HUGUES (FR); THOREL JEAN-NOEL (FR)
Applicant(s): SOC D EXPL FRANCAISE DES RECH (FR); GATTO HUGUES (FR); THOREL JEAN NOEL (FR)
Requested Patent: ☐ WO9621421
Application Number: WO1996FR00037 19960109
Priority Number(s): FR19950000327 19950109; FR19950000329 19950109
IPC Classification: A61K7/48
EC Classification: A61K7/48C6P, A61K7/48A, A61K7/48C22, A61K7/48C26D, A61K7/48C26D1, A61K45/06, C12N5/00M2, C12N5/06B12A
Equivalents: AU4492096, DE69611230D, DE69611230T, ☐ EP0802784 (WO9621421), B1, ES2153559T, JP10512253T

Abstract

A complex nutrient medium containing compounds that are biocompatible, biomimetic and bioavailable in the skin, but no biological extract of animal or cellular origin, for preparing a topical composition. Said complex nutrient medium has a suitable composition enabling viable in vitro culture of a human epidermal keratinocyte inoculum, with at least one clonal proliferation thereof during the first stage, and without the use of a live nutritive layer. The composition may be used as the active principle, particularly in a cosmetic preparation or a galenic base, and as a carrier capable of potentiating the activity of specific active principles.

Data supplied from the esp@cenet database - 12

FIG 1



FIG 2




08/860231-FIG 1

α^2 α^3 α^4 α^5 α^6 α^7 α^8 α^9 α^{10} α^{11} α^{12} α^{13} α^{14} α^{15} α^{16} α^{17} α^{18} α^{19} α^{20} α^{21} α^{22} α^{23} α^{24} α^{25} α^{26} α^{27} α^{28} α^{29} α^{30} α^{31} α^{32} α^{33} α^{34} α^{35} α^{36} α^{37} α^{38} α^{39} α^{40} α^{41} α^{42} α^{43} α^{44} α^{45} α^{46} α^{47} α^{48} α^{49} α^{50} α^{51} α^{52} α^{53} α^{54} α^{55} α^{56} α^{57} α^{58} α^{59} α^{60} α^{61} α^{62} α^{63} α^{64} α^{65} α^{66} α^{67} α^{68} α^{69} α^{70} α^{71} α^{72} α^{73} α^{74} α^{75} α^{76} α^{77} α^{78} α^{79} α^{80} α^{81} α^{82} α^{83} α^{84} α^{85} α^{86} α^{87} α^{88} α^{89} α^{90} α^{91} α^{92} α^{93} α^{94} α^{95} α^{96} α^{97} α^{98} α^{99} α^{100}



A



B



C

FIG 4

